Frigault Jonathan, Morin Geneviève, Drolet Sébastien, Bouchard Philippe, Bouchard Alexandre, Ngo Thanh-Quan Philips, Letarte François
Department of Surgery, CHU de Québec - Université Laval, Québec City, QC, Canada.
Ann Coloproctol. 2023 Aug;39(4):332-341. doi: 10.3393/ac.2022.00178.0025. Epub 2022 Nov 14.
Transanal total mesorectal excision (TaTME) has been proposed to overcome surgical difficulties encountered during rectal resection, especially for patients having high body mass index or low rectal cancer. The aim of this study was to evaluate oncologic outcomes following TaTME.
This retrospective study included all consecutive patients with rectal cancer who had a TaTME from 2013 to 2019. The main outcome was the incidence of locoregional recurrence by the end of the follow-up period.
Among a total of 81 patients, 96.3% were male, and their mean age was 63±9 years. The mean body mass index was 30.3±5.7 kg/m2, and the median distance from tumor to anal verge was 5.0 cm (interquartile range [IQR], 4.0-6.0 cm). Most patients had a low anterior resection performed (n=80, 98.8%) with a diverting ileostomy (n=64, 79.0%). Distal and circumferential resection margins were positive in 2.5% and 6.2% of patients, respectively. Total mesorectal excision was complete or near complete in 95.1% of patients. A successful resection was achieved in 72 patients (88.9%). After a median follow-up of 27.5 months (IQR, 16.7-48.1 months), 4 patients (4.9%) experienced locoregional recurrence. Anastomotic leaks were observed in 21 patients (25.9%). At the end of the follow-up, 69 patients (85.2%) were stoma-free.
TaTME was associated with acceptable oncological outcomes, including low locoregional recurrence rates in selected patients with low rectal cancer. Although associated with a high incidence of postoperative morbidities, the use of TaTME enabled a high rate of successful sphincter-saving procedures in selected patients who posed a technical challenge.
经肛门全直肠系膜切除术(TaTME)被认为可克服直肠切除术过程中遇到的手术困难,尤其是对于体重指数高或低位直肠癌患者。本研究旨在评估TaTME后的肿瘤学结局。
这项回顾性研究纳入了2013年至2019年期间所有连续接受TaTME的直肠癌患者。主要结局是随访期末局部区域复发的发生率。
在总共81例患者中,96.3%为男性,平均年龄为63±9岁。平均体重指数为30.3±5.7kg/m²,肿瘤距肛缘的中位距离为5.0cm(四分位间距[IQR],4.0 - 6.0cm)。大多数患者接受了低位前切除术(n = 80,98.8%)并进行了转流性回肠造口术(n = 64,79.0%)。分别有2.5%和6.2%的患者远端和环周切缘阳性。95.1%的患者全直肠系膜切除完整或接近完整。72例患者(88.9%)成功完成切除。中位随访27.5个月(IQR,16.7 - 48.1个月)后,4例患者(4.9%)出现局部区域复发。21例患者(25.9%)观察到吻合口漏。随访结束时,69例患者(85.2%)已无造口。
TaTME与可接受的肿瘤学结局相关,包括在选定的低位直肠癌患者中局部区域复发率较低。尽管术后并发症发生率较高,但对于存在技术挑战的选定患者,使用TaTME可实现较高的保肛成功率。